Experimental Hematology
Volume 30, Issue 10 , Pages 1170-1177 , October 2002

Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye

  • Ai-Hong Li

      Affiliations

    • Departments of Medical Biosciences and Pathology, Umeå University, Umeå, Sweden
    • ,
  • Erik Forestier

      Affiliations

    • Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden
    • ,
  • Richard Rosenquist

      Affiliations

    • Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden
    • ,
  • Göran Roos

      Affiliations

    • Corresponding Author InformationOffprint requests to: Göran Roos, M.D., Ph.D., Department of Medical Biosciences, Pathology, Umeå University, SE-90187 Umeå, Sweden
    • Departments of Medical Biosciences and Pathology, Umeå University, Umeå, Sweden

Received 28 March 2002 ,Revised 4 June 2002 ,Accepted 18 June 2002.

References 

  1. Pui CH. Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. Curr Opin Hematol. 1998;5:292
  2. Pui CH. Acute lymphoblastic leukemia. Pediatr Clin North Am. 1997;44:831
  3. Pui CH. Genetic studies in acute lymphoblastic leukemia. Acta Paediatr Taiwan. 2000;41:303
  4. Forestier E, Johansson B, Gustafsson G, et al.  Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia (a Nordic series comparing two treatment periods. For the Nordic Society of Paediatric Haematology and Oncology (NOPHO) Leukaemia Cytogenetic Study Group). Br J Haematol. 2000;110:147
  5. Pui CH. Childhood leukemias. N Engl J Med. 1995;332:1618
  6. Cave H, van der Werff ten Bosch J, Suciu S, et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer–Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339:591
  7. Coustan-Smith E, Sancho J, Hancock ML, et al.  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96:2691
  8. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731
  9. Deane M, McCarthy KP, Wiedemann LM, Norton JD. An improved method for detection of B-lymphoid clonality by polymerase chain reaction. Leukemia. 1991;5:726
  10. Potter MN, Steward CG, Maitland NJ, Oakhill A. Detection of clonality in childhood B-lineage acute lymphoblastic leukaemia by the polymerase chain reaction. Leukemia. 1992;6:289
  11. Steward CG, Goulden NJ, Katz F, et al.  A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor δ gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood. 1994;83:1355
  12. Li AH, Rosenquist R, Forestier E, et al.  Clonal rearrangements in childhood and adult precursor B acute lymphoblastic leukemia (a comparative polymerase chain reaction study using multiple sets of primers). Eur J Haematol. 1999;63:211
  13. Coyle LA, Papaioannou M, Yaxley JC, et al.  Molecular analysis of the leukaemic B cell in adult and childhood acute lymphoblastic leukaemia. Br J Haematol. 1996;94:685
  14. Breit TM, Wolvers-Tettero IL, Hahlen K, van Wering ER, van Dongen JJ. Extensive junctional diversity of gamma delta T-cell receptors expressed by T-cell acute lymphoblastic leukemias (implications for the detection of minimal residual disease). Leukemia. 1991;5:1076
  15. Macintyre E, d'Auriol L, Amesland F, et al.  Analysis of junctional diversity in the preferential V delta 1-J delta 1 rearrangement of fresh T-acute lymphoblastic leukemia cells by in vitro gene amplification and direct sequencing. Blood. 1989;74:2053
  16. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia (methodologic advances and clinical significance). Blood. 1995;85:1416
  17. van Dongen JJ, Szczepanski T, de Bruijn MA, et al.  Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther. 1996;2:121
  18. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731
  19. Kitchingman GR. Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia. Leukemia. 1994;8:395
  20. Cave H, Guidal C, Rohrlich P, et al.  Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood. 1994;83:1892
  21. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, et al.  Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia. 1998;12:2006
  22. Donovan JW, Ladetto M, Zou G, et al.  Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood. 2000;95:2651
  23. Bruggemann M, Droese J, Bolz I, et al.  Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia. 2000;14:1419
  24. Verhagen OJ, Willemse MJ, Breunis WB, et al.  Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia. 2000;14:1426
  25. Pfitzner T, Engert A, Wittor H, et al.  A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia. Leukemia. 2000;14:754
  26. Eckert C, Landt O, Taube T, et al.  Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2000;14:316
  27. Bohling SD, King TC, Wittwer CT, Elenitoba-Johnson KS. Rapid simultaneous amplification and detection of the MBR/JH chromosomal translocation by fluorescence melting curve analysis. Am J Pathol. 1999;154:97
  28. Nakao M, Janssen JW, Flohr T, Bartram CR. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology. Cancer Res. 2000;60:3281
  29. Gustafsson G, Schmiegelow K, Forestier E, et al.  Improving outcome through two decades in childhood ALL in the Nordic countries (the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO)). Leukemia. 2000;14:2267
  30. Li A-H, Rosenquist R, Forestier E, Lindh J, Roos G. Detailed clonality analysis of relapsing precursor B acute lymphoblastic leukemia (implications for minimal residual disease detection). Leuk Res. 2001;25:1033
  31. Rosenquist R, Thunberg U, Li AH, et al.  Clonal evolution as judged by immunoglobulin heavy chain gene rearrangements in relapsing precursor-B acute lymphoblastic leukemia. Eur J Haematol. 1999;63:171
  32. Billadeau D, Blackstadt M, Greipp P, et al.  Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction (a technique for sequential quantitation of residual disease). Blood. 1991;78:3021
  33. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med. 1997;336:317
  34. Brisco MJ, Sykes PJ, Hughes E, et al.  Comparison of methods for assessment of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia. Leukemia. 2001;15:385
  35. Cave H, van der Werff ten Bosch J, Suciu S, et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer–Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339:591
  36. Corradini P, Voena C, Omede P, et al.  Detection of circulating tumor cells in multiple myeloma by a PCR-based method. Leukemia. 1993;7:1879
  37. Kitchingman GR. Immunoglobulin heavy chain gene VH-D junctional diversity at diagnosis in patients with acute lymphoblastic leukemia. Blood. 1993;81:775
  38. Davi F, Gocke C, Smith S, Sklar J. Lymphocytic progenitor cell origin and clonal evolution of human B-lineage acute lymphoblastic leukemia. Blood. 1996;88:609
  39. Choi Y, Greenberg SJ, Du TL, et al.  Clonal evolution in B-lineage acute lymphoblastic leukemia by contemporaneous VH-VH gene replacements and VH-DJH gene rearrangements. Blood. 1996;87:2506
  40. Coustan-Smith E, Behm FG, Sanchez J, et al.  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351:550
  41. Brisco MJ, Condon J, Hughes E, et al.  Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Australian and New Zealand Children's Cancer Study Group. Leukemia. 1993;7:1514
  42. Gruhn B, Hongeng S, Yi H, et al.  Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia. 1998;12:675

PII: S0301-472X(02)00892-5

Experimental Hematology
Volume 30, Issue 10 , Pages 1170-1177 , October 2002

Article Tools

* Image Usage & Resolution